CRSP Overzicht aandelen
CRISPR Therapeutics AG, een bedrijf dat zich bezighoudt met genbewerking, richt zich op de ontwikkeling van op genen gebaseerde geneesmiddelen voor ernstige menselijke ziekten met behulp van zijn platform Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-geassocieerd eiwit 9 (Cas9).
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
CRISPR Therapeutics AG Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$50.76 |
| 52 Week Hoogtepunt | US$91.10 |
| 52 Week Laag | US$43.42 |
| Bèta | 1.67 |
| 11 maand verandering | 11.88% |
| 3 maanden verandering | 2.90% |
| 1 Jaar Verandering | -1.59% |
| 33 jaar verandering | -46.08% |
| 5 jaar verandering | -0.29% |
| Verandering sinds IPO | 260.26% |
Recent nieuws en updates
Crispr Therapeutics: Poised For A Major Turnaround
Oct 28CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected
Oct 02
Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres
Sep 13Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation
Sep 04Crispr's Casgevy Launch: Promising Start, Uncertain Future
Aug 14A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Aug 09Recent updates
Crispr Therapeutics: Poised For A Major Turnaround
Oct 28CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected
Oct 02Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres
Sep 13Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation
Sep 04Crispr's Casgevy Launch: Promising Start, Uncertain Future
Aug 14A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Aug 09Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
Aug 07Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle
Jul 13Crispr Therapeutics: Beaten Down But Not Broken
Jul 07CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk
Jun 18Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)
Jun 10Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)
Jun 03Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being
May 23Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts
May 13We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn
May 10Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg
May 09Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
May 03Crispr Therapeutics: Now Is The Time To Buy
Apr 24Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Apr 16Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Mar 26There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump
Feb 22Crispr Therapeutics: Cautiously Optimistic
Feb 22Crispr Therapeutics: Investors Bet Against Casgevy Uptake
Feb 01Crispr Therapeutics: Commercial Validation Is The Next Step
Jan 18Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry
Jan 11CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing
Dec 25CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Nov 02A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Oct 05CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price
Sep 14We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
Jul 24Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Jun 28CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Apr 02CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 06Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth
Dec 08CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag
Sep 28Crispr: Elucidating And Forecasting Key Developments
Sep 21Crispr Therapeutics: Nearing Harvest Season
Sep 08Rendement voor aandeelhouders
| CRSP | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 2.1% | -0.7% | -1.6% |
| 1Y | -1.6% | 19.8% | 30.8% |
Rendement versus industrie: CRSP underperformed the US Biotechs industry which returned 19.8% over the past year.
Rendement versus markt: CRSP underperformed the US Market which returned 30.8% over the past year.
Prijsvolatiliteit
| CRSP volatility | |
|---|---|
| CRSP Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: CRSP has not had significant price volatility in the past 3 months compared to the US market.
Volatiliteit in de loop van de tijd: CRSP's weekly volatility (6%) has been stable over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2013 | 407 | Sam Kulkarni | www.crisprtx.com |
CRISPR Therapeutics AG, een bedrijf dat zich bezighoudt met genbewerking, richt zich op de ontwikkeling van op genen gebaseerde geneesmiddelen voor ernstige menselijke ziekten met behulp van zijn Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-geassocieerd eiwit 9 (Cas9)-platform. CRISPR/Cas9 is een genbewerkingstechnologie die precieze gerichte veranderingen in genomisch DNA mogelijk maakt. Het bedrijf heeft een portefeuille van therapeutische programma's in een reeks van ziektegebieden, waaronder hemoglobinopathieën, immuun-oncologie en auto-immuun, in vivo, en type 1 diabetes.
CRISPR Therapeutics AG Samenvatting
| CRSP fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$4.49b |
| Inkomsten(TTM) | -US$265.80m |
| Inkomsten(TTM) | US$202.23m |
22.2x
P/S-verhouding-16.9x
Koers/WinstverhoudingIs CRSP overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| CRSP resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$202.23m |
| Kosten van inkomsten | US$484.70m |
| Brutowinst | -US$282.47m |
| Overige uitgaven | -US$16.67m |
| Inkomsten | -US$265.80m |
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -3.00 |
| Brutomarge | -139.68% |
| Nettowinstmarge | -131.44% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde CRSP op de lange termijn?
Bekijk historische prestaties en vergelijking